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Abstract 
 
Cardiovascular disease (CVD) is one of the most important causes of morbidity 
and mortality, and associated with an important economic burden globally. Over the last 
decade, the prevalence of CVD has been rising globally, and is now associated with 
millions of death annually in both developed and developing countries. There is good 
evidence that the immune system is involved in the pathophysiology of CVD. Toll-like 
receptors (TLRs) and their down-stream signaling pathways play an important role in 
the immune system. Recent studies have suggested that the TLRs are involved in 
atherogenesis, including stroke, myocardial infarction, ischemia-reperfusion injury, 
cardiac remodeling and development of heart failure (HF). In this review we have 
summarized the recent studies investigating the role of TLRs in CVD and the potential 
for using TLRs signaling pathways as a therapeutic target in CVD.  
Key words: cardiovascular disease, immune system, Toll-like receptors, signaling 
pathway 
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Introduction 
Cardiovascular disease (CVD) is a major health problem with a high prevalence 
of morbidity and mortality worldwide, and particularly in developing countries. Over the 
last decade, the prevalence of CVD has risen alarmingly and it is now estimated that 
about 17 million deaths, and a very high rate of complications result from CVD and this 
imposes huge economic burden on healthcare system (1, 2). Ischemic heart disease 
and cerebrovascular disease are responsible for a large percentage of patients with 
CVD (3). Although a number of studies have been performed to clarify the mechanisms 
involved in the pathogenesis of CVD, it remains a complex disease that is incompletely 
understood. Recently molecular investigations of CVD pathophysiology have revealed 
some interesting new insights, that may have a bearing on its treatment and prevention. 
Toll-like receptors (TLRs) and their signaling pathways have emerged as being 
potentially important  in the pathophysiology of CVD. 
The immune system has two main arms; the innate immune system (also called 
non-specific) and adaptive immune system (also called acquired or specific). The innate 
immune system plays a fundamental role as the first line of defensive mechanisms for 
sensing and eliminating invading pathogens (4). The Toll-like receptors (TLRs) are a 
group of receptors which related to a family of pattern recognition receptors (PRRs) that 
distinguish different molecular pattern of invading microbial pathogens called pathogen 
associated molecular patterns (PAMPs) (5). TLRs are expressed in various cell types, 
including immune cells and several non-immune cell types such as cardiovascular 
system cells (6, 7). After recognition of PAMPs the stimulation of TLRs results in multi-
steps events which finally activates expression of a variety of genes related to 
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inflammation and immune response (8-10). There is increasing evidence that shows 
that there are many interactions between the immune system and various human 
disease (7, 11). There are associations between polymorphisms of the TLRs and 
signaling pathways which are related with different diseases such as autoimmune 
diseases, diabetes, cancers and also cardiovascular disease (7). The TLRs are involved 
in many pathophysiological processes suggests that with pharmacological manipulation 
of TLRs pathway as one of these signaling pathways can be a potential target for 
therapeutic management of cardiovascular disease. The aim of this review is to 
summarize recent studies in exciting field of role of TLRs in CVD for improvement of 
understandings pathophysiology and using TLRs signaling pathways as a therapeutic 
target in CVD (Table 1-2). 
Characteristics of Toll-like receptors  
The Toll-like receptors (TLRs) are type I transmembrane glycoproteins, that play 
a role as a part of immune system which related to a family of pattern recognition 
receptors (PRRs) that distinguish different molecular pattern of invading microbial 
pathogens called pathogen associated molecular patterns (PAMPs) such as lipid, 
protein, lipoprotein and nucleic acid (5). TLRs have two major domains: an intracellular 
portion that called the Toll/IL-1 receptor (TIR) domain and extracellular portion which 
contains leucine-rich repeats (LRRs) (5). Eleven types of TLRs (TLR1-TLR11) have 
been identified in human and for recognition of cytoplasmic and extracellular PAMPs, 
some of them are localized on the cell surface and others exist in intracellular 
compartments, localized in endosome, lysosome, endolysosome and endoplasmic 
reticulum (6, 12). Cell surface TLRs include type 1, 2, 4, 5, 6, 10 and 11 and in contrast 
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to these TLRs, intracellular TLRs that known as antiviral TLRs include type 3, 7, 8 and 9 
(6). Stimulation of the TLR leads to initiating activation several signaling pathways which 
some of them are particular to specific type of TLR and some of them are common to all 
TLRs (6). TLRs are being expressed in various cell types, including immune cells in 
innate and adaptive system and several non-immune cell types such as fibroblast cells, 
endothelial cells and epithelial cells (13). The stimulation of TLRs results in a multi-step 
process which finally lads to the activation of regulatory pathways of the innate and 
adaptive immune system by producing inflammatory cytokines and other mediators 
(12). 
Toll-like receptors activation in immune and non-immune related conditions 
As mentioned above, TLRs can recognize conserved structural motifs of 
microbial pathogens known as PAMPs such as lipid, protein, lipoprotein and nucleic 
acid (5). For example, TLR2 recognizes specific components of cell wall in gram-
negative or positive bacteria, viruses, mycobacteria, parasites and fungi, TLR4 
recognizes lipopolysaccharide (LPS) of gram-negative bacteria and TLRs 3, 7, 8 and 9 
(14) bind with viral PAMPs. Other TLRs bind to protein ligands (14). It was 
demonstrated that dendritic cells as a one type of immune system cells can be activated 
without existence of microbial pathogen and host tissue injury (15). There has been 
increasing evidence that in certain conditions TLRs can be also be activated by non-
pathogen molecules such as host-derived molecule that could be release from tissues 
underwent physiological stress or any injury which is known as danger signal. These 
molecules are referred to as a danger-associated molecular pattern (DAMPs) include 
heat shock proteins (HSPs), fibronectin, fibrinogen, low-molecular-weight hyaluronic 
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acid, surfactant A protein, heparin sulfate, single- or double-strand RNA and high 
mobility group box-1 (HMGB-1) (16, 17). Alterations in the extracellular matrix could be 
a trigger for TLRs stimulation in the any presence of pathogens (6). Stimulation and 
activation of TLRs with host-derived molecules has risen attention to possible 
association between role of TLRs and CVD especially in development of atherosclerosis 
and heart failure.  
Toll-like receptors signaling and its association with microRNA 
TIR domain-containing adaptor molecules are different in TLRs signaling (18). At 
present, four major TIR domain-containing adaptors were identified: 1) myeloid 
differentiation factor 88 (MyD88), 2) TIR domain-containing adaptor protein (TIRAP), 3) 
TIR domain-containing adaptor inducing interferon β (TRIF), 4) TRIF-related adaptor 
molecule (TRAM) (6, 18). Following the recruitment of distinct adaptor molecules, 
downstream TLRs signaling can be separated into two different pathways: MyD88 
dependent and MyD88-independent signaling pathways, or the so-called TRIF 
dependent pathway. MyD88 is bound by all TLRs except TLR3 (19). Each signaling 
pathway results in activation of inflammatory gene transcription factors (including 
nuclear factor-κB (NF-κB), interferon-regulatory factors (IRFs), activator protein 1 (AP1) 
(19). On the other hand, it has been observed that there is crosstalk between TLRs 
signaling pathways and the phosphoinositide 3 kinase (PI3K)/ Akt signaling pathway, so 
that activation of each one could be able to activate the other (18). 
TIRAP is an essential molecule for connecting of TLR2 and TLR4 to MyD88 (18). 
After connection of MyD88 and activated TLR, MyD88 communicates with IL-1 receptor-
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associated kinases 4 (IRAK-4) and after that IRAK-4 stimulate IRAK-1 and IRAK-2. 
Following this, the IRAKs is separated from MyD88 and associate with tumor necrosis 
factor receptor-associated factor 6 (TRAF6). The complex of IRAKs and TRAF6 
associate with another membrane complex, and activates the complex consisting TAK1 
transforming growth factor-β-activated kinase 1 which also called mitogen-activated 
protein kinase kinase kinase 7 (MAP3K7), TAK1-binding protein 1 (TAB1), TAK1-
binding protein 2 (TAB2) and TAK1-binding protein 3 (TAB3) which phosphorylates the 
inhibitor of nuclear factor kappa B (NF-ҡB) kinase (IKK) and mitogen-activated protein 
kinase kinase 6 (MAP2K6) and other downstream molecules such as JUN N-terminal 
kinase (JNK), P38 and ERK activate NF-κB and AP-1. Subsequently NF-ҡB and AP-1 
translocate into the cellular nucleus and induce a number of gene transcription of 
proinflammatory cytokines and chemokines (16, 20, 21). 
In addition to MyD88-dependent signaling, there is another signaling pathway in 
which NF-ҡB activates in the absence of MyD88 association and known as MyD88-
independent signaling that in this signaling pathways the main adaptor protein are TRIF 
and TRAM. The TLR3 transduces its signal mainly via MyD88-independent signaling 
pathways (22). In addition to activation of the MyD88-dependent pathways, TRIF-
dependent pathways is another way that TLR7 and TLR9 could be able to transduce 
their signals and produce IFNs (10). TLR4 is able to transduce its signals via TRIF-
dependent pathways or MyD88 signaling pathways. In this pathway TRIF associates 
with TRAF family member-associated NF-kB activator (TANK)-binding kinase 1 (TBK1) 
and IKK-related kinases and IKK which make interferon regulatory factor 3 (IRF3) 
become active. IRF3 then transfer to the nucleus which leads to interferon (IFN-α and 
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IFN-β) production. The TRIF-dependent pathway may also lead to the activation of NF- 
ҡB (18). 
There is evidence of an association between the expression of microRNA 
(miRNA or miR) and regulation of TLRs-mediated signaling (18). miRNAs are short, 
non-coding RNA comprised of 19–22 nucleotides which play key roles in post-
transcriptionally regulation of many biological activities in the cells such as gene 
expression in cardiovascular and immune system cells (1). In this regard, Taganov et al. 
observed that TLR4 ligand could be able to increase miR-132, miR-146a and miR-155. 
As well, elevation in miR-146a expression also observed by TLR2 and TLR5 ligands 
(23). They also reported that TRAF6 and IRAK-1 are two targets of miR-146 (23). 
Similarly, O’Connell et al. showed that TLR3 and TLR4 ligands and IFN, enhance miR-
155 expression (24). Tili et al. have suggested that the expression of miR-155 increases 
the expression of TNF-α (25).They also reported that TLR4 ligand down-regulates miR-
125b expression. 
Role of TLRs signaling in atherosclerosis and angiogenesis 
Although the inflammatory nature of atherosclerosis process is well established, 
the potential factors driving the pro-inflammatory process are not fully established 
(Table 1-2) (6). In this regard, infectious factors such as chlamydia pneumonia and 
cytomegalovirus have previously been suggested as being involved in the development 
of plaque formation and act as TLRs ligand (26). Several studies have evaluated 
polymorphisms of the genes encoding TLRs in CVD. The most evaluated 
polymorphisms are Asp299Gly and Thr399Ile (6). Kiechl et al. in a cohort study 
evaluated the effect of Asp299Gly and Thr399Ile polymorphisms of the TLR4 gene in 
 9 
carotid artery atherosclerosis and found that subjects with specific alleles of these 
polymorphisms were associated with reduced risk of atherosclerosis and reduced 
intima-media thickness (27). However, later studies performed on larger sample size did 
not support this association (28-30). The relationship of these two polymorphisms and 
coronary artery disease (CAD) progression and risk of myocardial infarction (MI) have 
also been assessed. Several of these studies reported that the TLR4 Asp299Gly and 
Thr399Ile polymorphisms are associated with a reduced risk of MI (31-33). In contrast, 
Edfeldt et al. in an investigation of 2774 subjects reported that these polymorphisms 
were associated with an increased risk of MI in men, but not women (34). However Zee 
et al. and Koch et al. found no association between MI and these TLR4 polymorphisms 
(35, 36). Satoh and colleagues in 2005 evaluated serum proinflammatory cytokines and 
TLR4 expression on monocyte isolated from peripheral blood in patients with MI on 
admission and 14 days after MI and observed that baseline and after 14 days post MI 
onset; the expression of TLR4 and pro-inflammatory cytokines was higher in patients 
than healthy subjects. Also these levels were higher in patients with heart failure (HF) 
following a MI, than patients without HF (37). Methe et al. found that in patients with 
unstable angina (UA) and acute MI, levels of circulating TLR4-positive monocyte was 
significantly higher in UA than healthy subject and patients with stable angina (SA). In 
this study the increased level of TLR4 was associated with increased levels of IL-12 and 
B7-1 (38). In addition to atherosclerosis progression, there is evidence that TLRs might 
also have role in angiogenesis so that, activation of TLRs particularly TLR2, TLR4, 
TLR7 and TLR9 with activating ligands such as LPS could activate endothelial cell even 
without presence of further cytokines with the mechanisms of increased adenosine and 
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adenine nucleotide concentration in involved tissue which makes releasing endothelial 
growth factors and induct angiogenesis (39, 40). Recently, Carnevale et al. has 
proposed that TLR4 as well as gut derived LPS can play an important role in 
atherosclerosis process in human. They have found that Escherichia coli LPS can be 
localized in carotid plaque and facilitate formation of atherosclerotic lesion (41). LPS 
can amplify platelet responses to common agonists upon binding to its receptor, TLR4. 
It has been proven that platelet activation and aggregation requires an active TLR4 
pathway (42). Carnevale et al. study highlighted the possible role of bacterial LPS in 
atherosclerotic plaque formation via triggering the inflammation response through TLR4 
(41). According to this study, dietary modifications can play an important role in 
reducing the risk of cardiovascular disease. Although still controversial, drugs and diets 
which are helpful in lowering the circulating LPS and bacteria can possibly modify the 
atherosclerosis development in susceptible patients. Buerger’s disease is characterized 
by peripheral arterial occlusive disease in young male smoker and is mostly presented 
with limb ischemia and pain, intermittent claudication and severe limb ulcers. The 
molecular pathogenesis of this vascular disease is not fully understood. Recently, the 
role of TLRs in Buerger’s disease is being better understood. A single neucleotide 
polymorphisms in the MyD88 gene has been reported to be associated with Buerger’s 
disease (43). Both myeloid MyD88-dependent and independent TLR signaling pathways 
can result in monocyte adhesion and therefore, inflammatory response in vessel walls. 
TLR activators are newly developed immunomodulators that are proposed as possible 
therapeutic approaches for Buerger’s disease and other vascular disease with similar 
mechanisms   
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Role of TLRs signaling in myocardial ischemia-reperfusion injury 
Myocardial ischemia-reperfusion injury (IRI) is a condition that occurs after blood 
flow returns to myocardial tissue in an ischemic area after coronary artery occlusion 
(44). In this condition, neutrophil accumulation and excessive generation of oxygen 
radicals by ischemic myocardial and endothelial cells after restoration of blood supply 
result in further cellular damage and deleterious consequences (44). According to 
previous studies, TLRs are expressed in the myocardium are TLR2. TLR3. TLR4 and 
TLR6 and could be able to impact on myocardial disease (20, 45). Animal studies had 
shown that activation or conversely inhibition of activation of some of TLRs can cause 
adverse or favorable clinical effects, for example it was seen that stimulation of TLR4 
leads to reduction in cardiac myocyte apoptosis (46). The immune system plays an 
important role in IRI and therefore contributes to cardiac remodeling and incidence of 
heart failure (HF) but the exact involved mechanisms have not been clarified (47, 48). 
Recently a numbers of studies have indicated that the TLRs signaling pathway could be 
a treatment target in patients with MI. in this regard, activation of NF-kB after stimulation 
of TLRs after myocardial reperfusion has shown that related to increase myocardial 
damage and inhibition this activation could be beneficial in reducing myocardial injury 
and improve cardiac function (49-51). In an animal study, Eritoran a TLR4 blocker was 
reported to reduce infarct size after myocardial infarction (MI) (52). Other animal studies 
conducted on TLR4-deficient mice represent similar results by reducing inflammatory 
cell infiltration and cytokine expression (53-55). Consistent with these observations, in 
another study evaluated transgenic mice results showed that infarct size in MyD88-
deficient mice was significantly smaller. Furthermore, there was significantly better 
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cardiac function and less inflammatory cells infiltration to ischemic area after MI in these 
mice (56). Similarly, a study in IRAK4-deficient mice showed they were partially 
cardioprotected effects against IRI (57). Interestingly despite these results, in several 
animal studies it was reported that activation of TLR4 with administration of low dose of 
TLR4 agonists such as LPS 8-24 h before induction myocardial ischemia-reperfusion 
could be protective and reduced infarct size (58). This suggests that due to the 
existence of crosstalk between TLRs and PI3K/Akt signaling pathways activation of 
these signaling pathways modulated inflammatory responses and protect myocardial 
cells against apoptosis (59). It has been shown that PI3Kγ blockade is advantageous in 
cancer therapy. The blockade will result in both reduction of tumor growth and may also  
protect against anthracyclines cardiotoxicity (60). Moreover, TLR2 and TLR4 has been 
reported as an early markers of other drugs induced cardiomyopathy including 
doxorubicin. Patients who develop diastolic dysfunction will express higher rate of TLR2 
and TLR4 (61).  
Ha et al. observed that administration of a PI3K inhibitor eliminated the 
cardioprotection of pretreating with low dose of LPS (62). Furthermore, TLR2 plays a 
role in IRI so that although in several studies it was observed that TLR2 deficiency or 
the administration of anti-TLR2 antibody, before myocardial reperfusion results in 
decreased infarct size and cytokine secretion and improved cardiac function (63, 64), 
but in a study of Ha et al. administration of TLR2 agonist before reperfusion resulted in 
beneficial cardiac effects (18). Overall, cardiac protection induced by both TLR4 and 
TLR2 appear to be related to PI3K/Akt signaling and studies have revealed that 
inhibition of this pathway abolished cardiac protection of TLR2 and TLR4 (18, 65).  
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Role of TLRs signaling in post-MI cardiac remodeling and development of heart 
failure 
Due to negligible endogenous self-regenerative capacity of cardiomyocytes of 
human heart, elimination of necrotic cardiac tissue after MI and infiltration of immune 
cells ultimately leads to replacement with scar tissue (66). This is dependent of 
activation of immune system and production of cytokines which is a hallmark of MI (66). 
Although activation of TLRs-mediated signaling pathways as one of immune pathways 
in the early phase after MI, this may be beneficial but continuing this activation can 
accentuate detrimental remodeling in cardiac tissue injury and occurring heart failure 
(HF) which is defined as inability of pumping sufficient blood to different organs and 
tissues (67, 68).  The two important factors in patient outcome following an MI are: 
infarct size and left ventricular (LV) remodeling. Although the exact role of activation of 
TLRs in cardiac pathology is not fully-understood, but there are evidences that TLR4 is 
highly expressed in heart and has a major role in response of immune system after 
incidence of MI (69). Oyama et al. observed smaller infarct size and suppressed 
inflammation in mice with TLR4 deficiency (70). Shishido et al. found that TLR4 
deficiency was a protective condition in mice against adverse remodeling after 
MI.However, the infarct size was the same in mice with and without TLR2 deficiency, 
although TLR2-deficient mice had less TGF-β1 expression and type 1 collagen 
deposition, and also less fibrosis in histological examinations, ventricular remodeling 
and mortality (71). Furthermore, decreased LV remodeling and preserved systolic 
function in following MI was observed by Timmers et al. in TLR4-deficient mice. They 
also reported that although the collagen density was higher in the infarct area, 
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inflammatory cytokine expression was lower in TLR-4 deficient mice (72). On the other 
hand, Birks et al. showed that patients requiring left ventricular assist devices had 
higher levels of TLR4 and IL-1 receptor expression in their myocardium. They also 
observed significant association between expression of TLR4 and LI-1 receptor (49). 
Riad et al. reported that in mice with an induced MI, 6 days after MI those with TLR4 
deficiency had improved LV function, lower LV remodeling and level of atrial natriuretic 
peptide and collagen density (73). 
Role of TLRs signaling in septic cardiomyopathy and myocarditis 
Septic cardiomyopathy is systolic and diastolic dysfunction of both sides of the 
heart following infection (74). As mentioned above, bacterial components such as LPS 
are recognized by surface TLRs and bacterial or viral nucleic acids are recognized by 
intracellular TLRs (19). Consequently, TLRs especially TLR4 may be involved in septic 
cardiomyopathy and cardiac dysfunction. In animal models it was shown that TLR4 or 
IRAK1 deficiency are protective against septic cardiomyopathy (6). Results of the study 
conducted by Tavener et al. showed that administration of LPS to mice with TLR4-
deficient in myocardial cells but TLR4-positive in circulating leukocytes leads to 
impaired myocardial function. In contrast, giving LPS to TLR4-deficient in circulating 
leukocytes but positive in myocardial cells led to no change in cardiac function (75). 
However transplantation of TLR4-deficient bone marrow with the aim of cardioprotection 
did not lead to a positive effect (76). This could be because of roles of other TLRs such 
as TLR2 in myocardial cells or other tissues. In the studies investigated the role of TLR2 
in bacteria-induced cardiomyopathy, results revealed the protective effect of TLR2-
deficient condition during sepsis (77). Although the effect of Eritoran administration, a 
 15 
synthetic TLR4 antagonist, in prevention of cardiomyopathy in severe septic patients 
are not fully demonstrated, Tidswell et al. in their clinical trial reported no significant 
reduction in all-causes mortality in patients with severe sepsis by administration of 
Eritoran (78). 
The most common cause of acute myocarditis is viral infection (19). The immune 
system and its responses are active in the subclinical phase of myocarditis (79). The 
definite diagnosis of myocarditis is made by endomyocardial biopsy and its histological 
evaluation (80). Activation of host immune response and TLRs signaling following viral 
infection and replication produce a variety of inflammatory cytokines that make 
infiltration of inflammatory cells found to be important factors with protective or 
deleterious effects on incidence of myocarditis and cardiomyopathy (81, 82). TLRs can 
be activated by double or single stranded RNA such as TLR3 have more correlation 
with viral myocarditis (19). Despite many animal studies on the roles of TLRs in 
pathogenesis of myocarditis, there is little clinical data available. In an animal model 
study, Negishi et al. evaluated the role of TLR3 signaling pathway in infection with 
coxsackie virus, TLR3 deficient mice was more susceptible to be infected by some viral 
infection such as Coxsackie virus, whilst expression of TLR3 makes resistant against 
viruses (83). It was seen that TLR3 is important in controlling infection caused by 
Coxsackie virus due to subsequent activation of anti-viral infection (19). In viral 
myocarditis in mice deficient in TLR3 due to more viral replication in the primary phase, 
results in greater myocardial injury and increases risk of adverse clinical outcome (84). 
Also it was observed that in these mice infection with encephalomyocarditis virus 
resulted in more severe cardiac damage and earlier death (19). Gorbea et al. showed a 
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polymorphism of TLR3 gene in patients diagnosed with enteroviral myocarditis, reduce 
the ability to inhibit viral replication because of decrease in type I interferon (85). As 
mentioned previously, TLR3 transduces its signal through TRIF-dependent pathways. 
Although the presence of TLR3 inhibits viral replication, activation of TRIF which 
possesses pro-apoptotic activity, could give viruses, which are the obligatory 
intracellular pathogens, to replicate in infected cells. Therefore more studies should be 
undertaken to clarify its role in viral infection. On the other hand, it has been suggested 
that after viral infection, TLR4 deficient mice showed significantly lower viral replication 
in myocytes and reduced production of IL-1β and IL-18 and therefore less severe 
myocarditis (86). In this regard, Satoh et al. investigated 44 patients with myocarditis 
and found higher levels of TLR4 in these patients compared with control group. In 
addition, they found a positive association between the level of enteroviral RNA and 
TLR4 level (87). Pauschinger et al. observed that a greater enteroviral RNA level 
correlated with left ventricular dysfunction (88). Furthermore, Fuse et al. reported that 
Absence of MyD88 is associated with higher survival rate and lower viral load and 
reduction of production of interferon-γ (IFN- γ), IL-18, tumor necrosis factor-α (TNF-α) 
and cytokines of T-helper 1. However levels of IFN-β were significantly increased (89).  
Role of TLRs signaling in infective endocarditis 
Infective endocarditis (IE) is an important cardiac disease with a high mortality rate and 
in spite of available treatments its prognosis is poor (90). Several studies have reported 
the relationship between TLRs and pathogenesis of IE. Bustamante et al. investigated 
R753Q and R677W polymorphisms of TLR2 and D299G and T399I polymorphisms of 
TLR4 in 65 patients with IE and 66 healthy participants, and report that the TLR2 
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R735Q polymorphism was significantly associated with endocarditis and presence of 
this polymorphism makes individuals more susceptible to development of infective 
endocarditis (91). Golovkin et al. also investigated several polymorphisms of TLRs: 
rs5743551 and rs5743611 of TLR1, rs3804099 and rs5743708 of TLR2, rs4986790 and 
rs4986791 of TLR4 and rs3775073 and rs5743810 of TLR6. One hundred ten patients 
with infective endocarditis and 300 healthy matched participants were evaluated. They 
concluded that among mentioned polymorphisms, only TLR6 rs3775073 polymorphism 
was significantly correlated with decreased risk of IE (92). Single nucleotide variants of 
TLR4 were investigated by Weinstock et al. using blood that was obtained from 148 
patients with IE and 185 controls. No significant difference in genetic variants of TLR4 
was found between IE and control groups (93). Tsaganos et al. in their animal study 
induced bacterial endocarditis by two types of staphylococcus aureus, methicillin-
susceptible (MSSA) and methicillin-resistant (MRSA), in rabbits. Results showed that 
after addition of TLR4 antagonist, infection with MSSA resulted in higher stimulation of 
TNF-α. This study revealed different pattern of TNF-α stimulation, independent to TLR4 
mechanisms in MSSA and MRSA endocarditis (94). Banks et al. investigated 
Streptococcus sanguis as one of main causes of IE. They observed that the secreted 
components of this bacteria which was able to inhibit activation of monocytes by binding 
to a complex of TRL4 and CD14 (Table 1-2)(95). 
Role of TLRs signaling in atrial fibrillation 
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia (96) and MI is 
an independent risk factor of new-onset AF (97). It has been reported that TLRs and its 
associated inflammation may be correlated with AF. Therefore they can be used as 
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potential predictor of new-onset AF after MI. In this regard, Zhang et al. investigated 
TLRs in peripheral blood mononuclear cell in 84 patients with MI and 85 patients with 
new-onset AF after MI. Eighty-two healthy individuals were selected as control group. 
Results showed significantly higher expression of TLR2 and TLR4 and their signaling 
proteins in group of patients with AF compared with MI patients without AF and also 
control group (97). Similarly, eighty six patients with AF and 86 participants with sinus 
rhythm were enrolled in a study conducted by Gurses and colleagues. The expression 
of TLR2 and TLR4 in peripheral blood monocyte were evaluated. At the end of the 
study, they found that AF patients had significantly higher TLR2 and TLR4. As well, 
after 17 months follow they found that the expression level of monocyte TLR4 was 
independent predictor of AF recurrence. These results suggest that TLR4 may be a 
potential therapeutic target in AF patients (96). Consistent with this result, Gurses et al. 
evaluation platelet TLR2, TLR4 and HMGB-1 in 53 AF patients and 22 controls. Left 
atrial and peripheral blood were obtained. This study showed significantly higher level of 
peripheral blood and left atrial TLR2, TLR4 and HMGB-1 in AF patients. Patients with 
persistent AF had higher serum HMGB-1 and also left atrial platelet TLR2 and TLR4 
than patients with paroxysmal AF (98). Wang et al. found that patients with AF had 
higher level of TLR2 compared to controls and in contrast to a previous study 
comparison two group of AF patients revealed that TLR2 was significantly higher in 
paroxysmal AF than persistent AF patients (99). The most important complication of AF 
is atrial thrombi formation which can be resulted in ischemic accidents such as ischemic 
stroke (98). Association between TLRs signaling and thrombosis in patients with AF 
was investigated by Xu et al. with evaluation three groups: 15 AF patients without 
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thrombus, 15 AF patients with thrombus and 15 participants with sinus rhythm. 
Ultimately, they observed that in comparison to other groups, MyD88 and HMGB1 were 
significantly higher in AF patients with thrombus. However expression level of TLR4 was 
not different between three groups (100).  
Role of TLRs signaling in cerebrovascular disease 
Cerebrovascular diseases refer to conditions in which the blood vessels 
supplying the brain are primarily involved (101). The most common manifestation of this 
group of disease is stroke that can be occurred as an ischemic or hemorrhagic which 
can cause major disability and mortality (101). Different endogenous ligands such as 
high-mobility group box 1 (HMGB1) protein, heat shock proteins (HSPs), hyaluronic acid 
and mRNA are released from damaged cells following to CNS injuries could be able to 
activate TLRs signaling pathways and result in triggers immune responses and 
infiltration of inflammatory elements and therefore further neuronal damage (102). 
Although the exact roles of TLRs in cerebrovascular disease is not fully-understood, two 
aspect of their effects have been suggested in stroke: on one hand the neuroprotective 
effects and neurodegenerative effects on the other hand. In this regard one of the 
important factors in outcomes resulted from activation of TLRs in nervous system 
depends on type of involved cells express TLR and another one is time course. It has 
been observed that TLRs activation could lead to the expression of anti-inflammatory 
cytokines such as IL-10 production that result in barricade neurodegenerative of several 
cytokines such as IFN-γ and TNF-α (103, 104). Samarasinghe et al. have reported that 
12-24 h after activation of TLRs, the levels of serum IL-10 was raised (105). MyD88 
deficient hematopoietic cells were investigated by Downes et al. who observed that 
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MyD88 deficient mice had a larger cerebral infarct size (106). Microglial cells have key 
role in stroke pathogenesis and study conducted by Jung et al. showed that the 
inhibition of activation of TLR4 leads to the release of IFN-β which contributes to 
induction of apoptosis in these cells (107). Aravalli et al. observed that blocking of TLR2 
signaling pathway prevent progression of microglial cells towards apoptosis (108). 
Stevens et al. found that blockage of TLR9 also leads to neuroprotection (109). Tang et 
al. found that within 1 h after incidence of ischemic stroke the expression of TLR2 and 
TLR4 by neurons was elevated (110) and within 24 h microglial cells in ischemic area 
express high TLR2. This means activation of neuronal response prior to activation of 
microglial cells. Cao et al. showed that a reduced infarct size and lower levels of 
proinflammatory cytokines and overall better outcome in TLR2 and also TLR4 deficient 
mice with brain ischemia (111). Hyakkoku et al. confirmed these findings (112). Tang et 
al. concluded that activation of TLR 2 and TLR4 expressed by neurons with activation of 
caspase 3 can result in apoptosis (110). However, no significant difference was 
reported by Brea et al. in expression of TLR3 and TLR9 between good outcome and 
poor outcome in evaluation of 110 patients with ischemic stroke (113). Yang et al. found 
a correlation between higher TLR4 level in monocytes in peripheral blood and adverse 
neurological outcome (114). A positive association was also found by Ferronato et al. 
between TLR4 expression and expression of cyclooxygenase-2 (COX-2), an enzyme 
important in inflammation, after ischemic stroke which can cause more CNS damage 
(115). miRNAs act as key regulators of the expression of different genes post-
transcriptionally (1). Xu et al. found high levels of miR-1906 in the ischemic zone and 
also in a peri-ischemic zone. They also found that after administration of exogenous 
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miR-1906, the expression of TLR4 and infarct zone was reduced and neurological 
functional outcomes were improved. However this protective effect was not seen in 
TLR4 knockout mice (116). Lin et al. investigated TLR4 gene polymorphisms among 
ethnic Chinese people and observed that Asp119Cys polymorphism significantly 
correlated with increased risk of ischemic stroke (117). 
Role of TLRs in therapeutic effect of cardiac stem cell therapy and bacteria based 
approaches 
Rejection of cardiac stem cells is a major limitation of stem cell therapy that is 
mostly due to low tolerance of transplanted cells against hypoxia and inflammation 
which leads to apoptosis (Table 1-2). Disrupting the immune response is considered as 
a possible solution for improving the survival of transplanted stem cells. Modulation of 
toll like receptors is an interesting issue which under active research. TLR1-TLR6 and 
TLR9 which are expressed on outer surface or within intracellular organelles of 
mesenchymal stem cells (10, 118). TLRs signaling pathways can be activated by 
endogenous molecule secreted from damaged tissue. TLR4 is a well-known example of 
this issue. LPS which is a ligand for TLR4 will promote releasing of proinflammatory 
factors and prevent stem cell apoptosis (119, 120). Preconditioning of mesenchymal 
stem cells with LPS will results in better engraftment and greater survival rate of stem 
cells. Also it has been reported that angiogenesis will be enhanced by releasing of 
vascular endothelial growth factor (VEGF) (121). As well, activation of TLR3 will 
increase immunosuppressive capacity of transplanted stem cell by releasing 
immunosuppressive factors (120). 
 22 
As mentioned earlier, TLRs play an important role in inflammation and inflammatory 
pathways. According the complexity of inflammatory pathways, there is still controversy 
about the exact therapeutic effect of TLR targeting. Activation of TLR will result in 
inflammatory response and this phenomenon has been reported with Escherichia coli 
and chlamydia infection (41, 122). Despite the established effect of gut microbiota on 
various metabolic and cardiovascular conditions, the role of antibiotic therapy on gut 
microbiota is not widely studied. Antibiotics can alter microbiota and induce or prevent 
some disease (123). By selective disruption of gut microbiota a certain bacteria can be 
targeted. Using highly specific antibiotics will eradicate a specific bacteria and therefore 
may interfere with specific pathways such as inflammation or atherogenesis. Another 
emerging issue about the therapeutic approaches for cardiovascular disease are 
probiotics. It has been suggested that use of different strains may interact with TLR and 
suppress inflammatory cytokine production (124). However, despite of recent trends 
toward new therapeutic approaches for cardiovascular disease, use of probiotics and 
selective antibiotics is not widely studied and the available data is controversial.         
 
Conclusion: 
Cardiovascular disease is among the leading cause death. Toll-like receptors 
and their down-stream signaling pathways play a crucial role in the immune system and 
its potential link with myocardial infarction, and heart failure, which is activated via 
endogenous molecule secreted from damaged tissue, indicating its value as a 
therapeutic target. Atherosclerosis is associated with inflammation and involvement of 
immune responses. TLR play an important role in macrophage activation within 
atherosclerotic lesions. There is growing body of data on TLR inhibitors and agonists in 
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clinical trials for inflammatory conditions such as asthma, cancer, and autoimmune 
diseases, although studies in the context of CVD is in its infancy and many questions 
are still remained unanswer, therefore a deeper understanding of the role of TLRs in 
cardiovascular diseases via further experimental studies including randomized 
controlled trials, are warranted.  
 
 24 
References 
 
1. Parizadeh SM, Ferns GA, Ghandehari M, Hasanian SM, Ghayour‐Mobarhan M, Parizadeh SMR, et 
al. The diagnostic and prognostic value of circulating microRNAs in coronary artery disease: a novel 
approach to disease diagnosis of stable CAD and acute coronary syndrome. Journal of cellular 
physiology. 2017. 
2. Xu J-Y, Chen G-H, Yang Y-J. Exosomes: a rising star in failing hearts. Frontiers in physiology. 
2017;8:494. 
3. Norhammar A, Schenck-Gustafsson K. Type 2 diabetes and cardiovascular disease in women. 
Diabetologia. 2013;56(1):1-9. 
4. Hori M, Nishida K. Toll-like receptor signaling: defensive or offensive for the heart? : Am Heart 
Assoc; 2008. 
5. Medzhitov R. Toll-like receptors and innate immunity. Nature Reviews Immunology. 
2001;1(2):135. 
6. Frantz S, Ertl G, Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular 
disease. Nature Reviews Cardiology. 2007;4(8):444. 
7. Moradi‐Marjaneh R, Hassanian SM, Fiuji H, Soleimanpour S, Ferns GA, Avan A, et al. Toll like 
receptor signaling pathway as a potential therapeutic target in colorectal cancer. Journal of cellular 
physiology. 2017. 
8. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. 
Nature. 2000;406(6797):782. 
9. Anderson KV. Toll signaling pathways in the innate immune response. Current opinion in 
immunology. 2000;12(1):13-9. 
10. Ha T, Liu L, Kelley J, Kao R, Williams D, Li C. Toll-like receptors: new players in myocardial 
ischemia/reperfusion injury. Antioxidants & redox signaling. 2011;15(7):1875-93. 
11. Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury 
and repair. Nature Reviews Immunology. 2015;15(2):117. 
12. Kawasaki T, Kawai T. Toll-like receptor signaling pathways. Frontiers in immunology. 2014;5:461. 
13. Delneste Y, Beauvillain C, Jeannin P. Innate immunity: structure and function of TLRs. Medecine 
sciences: M/S. 2007;23(1):67-73. 
14. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 
2006;124(4):783-801. 
15. Gallucci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. 
Nature medicine. 1999;5(11):1249. 
16. Moghimpour Bijani F, Vallejo JG, Rezaei N. Toll-like receptor signaling pathways in cardiovascular 
diseases: challenges and opportunities. International reviews of immunology. 2012;31(5):379-95. 
17. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune 
system to dying cells. Nature. 2003;425(6957):516. 
18. Ha T, Hu Y, Liu L, Lu C, McMullen JR, Kelley J, et al. TLR2 ligands induce cardioprotection against 
ischaemia/reperfusion injury through a PI3K/Akt-dependent mechanism. Cardiovascular research. 
2010;87(4):694-703. 
19. Hofmann U, Ertl G, Frantz S. Toll-like receptors as potential therapeutic targets in cardiac 
dysfunction. Expert opinion on therapeutic targets. 2011;15(6):753-65. 
 25 
20. Frantz S, Kobzik L, Kim Y-D, Fukazawa R, Medzhitov R, Lee RT, et al. Toll4 (TLR4) expression in 
cardiac myocytes in normal and failing myocardium. The Journal of clinical investigation. 
1999;104(3):271-80. 
21. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor 
protein in the hToll/IL-1 receptor family signaling pathways. Molecular cell. 1998;2(2):253-8. 
22. Vallejo JG. Role of toll-like receptors in cardiovascular diseases. Clinical science. 2011;121(1):1-
10. 
23. Taganov KD, Boldin MP, Chang K-J, Baltimore D. NF-κB-dependent induction of microRNA miR-
146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National 
Academy of Sciences. 2006;103(33):12481-6. 
24. O'Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during 
the macrophage inflammatory response. Proceedings of the National Academy of Sciences. 
2007;104(5):1604-9. 
25. Tili E, Michaille J-J, Cimino A, Costinean S, Dumitru CD, Adair B, et al. Modulation of miR-155 and 
miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the 
response to endotoxin shock. The Journal of Immunology. 2007;179(8):5082-9. 
26. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-
43. 
27. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 
4 polymorphisms and atherogenesis. New England Journal of Medicine. 2002;347(3):185-92. 
28. Labrum R, Bevan S, Sitzer M, Lorenz M, Markus HS. Toll receptor polymorphisms and carotid 
artery intima-media thickness. Stroke. 2007;38(4):1179-84. 
29. Netea M, Hijmans A, Van Wissen S, Smilde T, Trip M, Kullberg B, et al. Toll‐like receptor‐4 
Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial 
hypercholesterolaemia. European journal of clinical investigation. 2004;34(2):94-9. 
30. Norata G, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, et al. Effect of the Toll‐like 
receptor 4 (TLR‐4) variants on intima‐media thickness and monocyte‐derived macrophage response to 
LPS. Journal of internal medicine. 2005;258(1):21-7. 
31. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont M-C, Seknadji P, et al. Association of 
the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arteriosclerosis, 
thrombosis, and vascular biology. 2003;23(12):e61-e4. 
32. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, et al. 
Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. 
Circulation. 2003;107(19):2416-21. 
33. Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to 
myocardial infarction. Pharmacogenetics and genomics. 2005;15(1):15-21. 
34. Edfeldt K, Bennet AM, Eriksson P, Frostegård J, Wiman B, Hamsten A, et al. Association of hypo-
responsive toll-like receptor 4 variants with risk of myocardial infarction. European heart journal. 
2004;25(16):1447-53. 
35. Koch W, Hoppmann P, Pfeufer A, Schömig A, Kastrati A. Toll-like receptor 4 gene polymorphisms 
and myocardial infarction: no association in a Caucasian population. European Heart Journal. 
2006;27(21):2524-9. 
36. Zee RY, Hegener HH, Gould J, Ridker PM. Toll-like receptor 4 Asp299Gly gene polymorphism and 
risk of atherothrombosis. Stroke. 2005;36(1):154-7. 
37. Satoh M, Shimoda Y, Maesawa C, Akatsu T, Ishikawa Y, Minami Y, et al. Activated toll-like 
receptor 4 in monocytes is associated with heart failure after acute myocardial infarction. International 
journal of cardiology. 2006;109(2):226-34. 
 26 
38. Methe H, Kim J-O, Kofler S, Weis M, Nabauer M, Koglin J. Expansion of circulating Toll-like 
receptor 4–positive monocytes in patients with acute coronary syndrome. Circulation. 
2005;111(20):2654-61. 
39. Montesinos MC, Desai A, Chen J-F, Yee H, Schwarzschild MA, Fink JS, et al. Adenosine promotes 
wound healing and mediates angiogenesis in response to tissue injury via occupancy of A2A receptors. 
The American journal of pathology. 2002;160(6):2009-18. 
40. Pollet I, Opina CJ, Zimmerman C, Leong KG, Wong F, Karsan A. Bacterial lipopolysaccharide 
directly induces angiogenesis through TRAF6-mediated activation of NF-κB and c-Jun N-terminal kinase. 
Blood. 2003;102(5):1740-2. 
41. Carnevale R, Nocella C, Petrozza V, Cammisotto V, Pacini L, Sorrentino V, et al. Localization of 
lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque. Scientific reports. 
2018;8(1):3598. 
42. Zhang G, Han J, Welch EJ, Richard DY, Voyno-Yasenetskaya TA, Malik AB, et al. 
Lipopolysaccharide stimulates platelet secretion and potentiates platelet aggregation via TLR4/MyD88 
and the cGMP-dependent protein kinase pathway. The Journal of Immunology. 2009;182(12):7997-
8004. 
43. Chen Z, Nakajima T, Inoue Y, Kudo T, Jibiki M, Iwai T, et al. A single nucleotide polymorphism in 
the 3′-untranslated region of MyD88 gene is associated with Buerger disease but not with Takayasu 
arteritis in Japanese. Journal of human genetics. 2011;56(7):545. 
44. Buja LM. Myocardial ischemia and reperfusion injury. Cardiovascular Pathology. 2005;14(4):170-
5. 
45. Re F, Strominger JL. Toll-like receptor 2 (TLR2) and TLR4 differentially activate human dendritic 
cells. Journal of Biological Chemistry. 2001;276(40):37692-9. 
46. Zhu X, Zhao H, Graveline AR, Buys ES, Schmidt U, Bloch KD, et al. MyD88 and NOS2 are essential 
for toll-like receptor 4-mediated survival effect in cardiomyocytes. American Journal of Physiology-Heart 
and Circulatory Physiology. 2006;291(4):H1900-H9. 
47. Barry WH. Mechanisms of immune-mediated myocyte injury. Circulation. 1994;89(5):2421-32. 
48. Bozkurt B, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, et al. Pathophysiologically 
relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and 
remodeling in rats. Circulation. 1998;97(14):1382-91. 
49. Birks EJ, Felkin LE, Banner NR, Khaghani A, Barton PJ, Yacoub MH. Increased toll-like receptor 4 
in the myocardium of patients requiring left ventricular assist devices. The Journal of heart and lung 
transplantation. 2004;23(2):228-35. 
50. Li C, Browder W, Kao RL. Early activation of transcription factor NF-κB during ischemia in 
perfused rat heart. American Journal of Physiology-Heart and Circulatory Physiology. 1999;276(2):H543-
H52. 
51. Li C, Ha T, Kelley J, Gao X, Qiu Y, Kao RL, et al. Modulating Toll-like receptor mediated signaling 
by (1→ 3)-β-D-glucan rapidly induces cardioprotection. Cardiovascular Research. 2004;61(3):538-47. 
52. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, et al. Inhibition of Toll-like 
receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation. 2006;114(1 
suppl):I-270-I-4. 
53. Ao L, Zou N, Cleveland JC, Fullerton DA, Meng X. Myocardial TLR4 is a determinant of neutrophil 
infiltration after global myocardial ischemia: mediating KC and MCP-1 expression induced by 
extracellular HSC70. American Journal of Physiology-Heart and Circulatory Physiology. 2009;297(1):H21-
H8. 
54. Chong AJ, Shimamoto A, Hampton CR, Takayama H, Spring DJ, Rothnie CL, et al. Toll-like 
receptor 4 mediates ischemia/reperfusion injury of the heart. The Journal of thoracic and cardiovascular 
surgery. 2004;128(2):170-9. 
 27 
55. Fallach R, Shainberg A, Avlas O, Fainblut M, Chepurko Y, Porat E, et al. Cardiomyocyte Toll-like 
receptor 4 is involved in heart dysfunction following septic shock or myocardial ischemia. Journal of 
molecular and cellular cardiology. 2010;48(6):1236-44. 
56. Feng Y, Zhao H, Xu X, Buys ES, Raher MJ, Bopassa JC, et al. Innate immune adaptor MyD88 
mediates neutrophil recruitment and myocardial injury after ischemia-reperfusion in mice. American 
Journal of Physiology-Heart and Circulatory Physiology. 2008;295(3):H1311-H8. 
57. Maekawa Y, Mizue N, Chan A, Shi Y, Liu Y, Dawood S, et al. Survival and cardiac remodeling after 
myocardial infarction are critically dependent on the host innate immune interleukin-1 receptor-
associated kinase-4 signaling: a regulator of bone marrow-derived dendritic cells. Circulation. 
2009;120(14):1401-14. 
58. Zacharowski K, Frank S, Otto M, Chatterjee PK, Cuzzocrea S, Hafner G, et al. Lipoteichoic acid 
induces delayed protection in the rat heart: a comparison with endotoxin. Arteriosclerosis, thrombosis, 
and vascular biology. 2000;20(6):1521-8. 
59. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in 
vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation. 2000;101(6):660-7. 
60. Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, et al. Phosphoinositide 3-Kinase 
Gamma Inhibition Protects from Anthracycline Cardiotoxicity and Reduces Tumor Growth. Circulation. 
2018:CIRCULATIONAHA. 117.030352. 
61. Pop-Moldovan A, Trofenciuc N-M, Dărăbanţiu D, Precup C, Branea H, Christodorescu R, et al. 
Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early 
detection of doxorubicin-induced cardiotoxicity. Cancer gene therapy. 2017;24(5):203. 
62. Ha T, Hua F, Liu X, Ma J, McMullen JR, Shioi T, et al. Lipopolysaccharide-induced myocardial 
protection against ischaemia/reperfusion injury is mediated through a PI3K/Akt-dependent mechanism. 
Cardiovascular research. 2008;78(3):546-53. 
63. Arslan F, Smeets MB, O'neill LA, Keogh B, McGuirk P, Timmers L, et al. Myocardial 
ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic 
administration of a novel anti–toll-like receptor-2 antibody. Circulation. 2010;121(1):80-90. 
64. Favre J, Musette P, Douin-Echinard V, Laude K, Henry J-P, Arnal J-F, et al. Toll-like receptors 2-
deficient mice are protected against postischemic coronary endothelial dysfunction. Arteriosclerosis, 
thrombosis, and vascular biology. 2007;27(5):1064-71. 
65. Hua F, Ha T, Ma J, Li Y, Kelley J, Gao X, et al. Protection against myocardial ischemia/reperfusion 
injury in TLR4-deficient mice is mediated through a phosphoinositide 3-kinase-dependent mechanism. 
The Journal of Immunology. 2007;178(11):7317-24. 
66. Frangogiannis NG. The mechanistic basis of infarct healing. Antioxidants & redox signaling. 
2006;8(11-12):1907-39. 
67. Navi A, Patel H, Shaw S, Baker D, Tsui J. Therapeutic role of toll-like receptor modification in 
cardiovascular dysfunction. Vascular pharmacology. 2013;58(3):231-9. 
68. Topkara VK, Evans S, Zhang W, Epelman S, Staloch L, Barger PM, et al. Therapeutic targeting of 
innate immunity in the failing heart. Journal of molecular and cellular cardiology. 2011;51(4):594-9. 
69. Frangogiannis NG. The immune system and cardiac repair. Pharmacological research. 
2008;58(2):88-111. 
70. Oyama J-i, Blais C, Liu X, Pu M, Kobzik L, Kelly RA, et al. Reduced myocardial ischemia-
reperfusion injury in toll-like receptor 4-deficient mice. Circulation. 2004;109(6):784-9. 
71. Shishido T, Nozaki N, Yamaguchi S, Shibata Y, Nitobe J, Miyamoto T, et al. Toll-like receptor-2 
modulates ventricular remodeling after myocardial infarction. Circulation. 2003;108(23):2905-10. 
72. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans M-J, et al. Toll-like 
receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after 
myocardial infarction. Circulation research. 2008;102(2):257-64. 
 28 
73. Riad A, Jäger S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D, et al. Toll-like receptor-4 
modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. The 
Journal of Immunology. 2008;180(10):6954-61. 
74. Vieillard-Baron A. Septic cardiomyopathy. Annals of intensive care. 2011;1(1):6. 
75. Tavener SA, Long EM, Robbins SM, McRae KM, Van Remmen H, Kubes P. Immune cell Toll-like 
receptor 4 is required for cardiac myocyte impairment during endotoxemia. Circulation research. 
2004;95(7):700-7. 
76. Binck BW, Tsen MF, Islas M, White DJ, Schultz RA, Willis MS, et al. Bone marrow-derived cells 
contribute to contractile dysfunction in endotoxic shock. American Journal of Physiology-Heart and 
Circulatory Physiology. 2005;288(2):H577-H83. 
77. Zou L, Feng Y, Chen Y-J, Si R, Shen S, Zhou Q, et al. Toll-like receptor 2 plays a critical role in 
cardiac dysfunction during polymicrobial sepsis. Critical care medicine. 2010;38(5):1335. 
78. Tidswell M, Tillis W, LaRosa SP, Lynn M, Wittek AE, Kao R, et al. Phase 2 trial of eritoran 
tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Critical care 
medicine. 2010;38(1):72-83. 
79. Hill SL, Rose NR. The transition from viral to autoimmune myocarditis. Autoimmunity. 
2001;34(3):169-76. 
80. Zimmermann O, Kochs M, Zwaka TP, Kaya Z, Lepper PM, Bienek-Ziolkowski M, et al. Myocardial 
biopsy based classification and treatment in patients with dilated cardiomyopathy. International journal 
of cardiology. 2005;104(1):92-100. 
81. Satoh M, Nakamura M, Satoh H, Saitoh H, Segawa I, Hiramori K. Expression of tumor necrosis 
factor-alpha–converting enzyme and tumor necrosis factor-alpha in human myocarditis. Journal of the 
American College of Cardiology. 2000;36(4):1288-94. 
82. Satoh M, Segawa I, Tashiro A, Hiramori K, Tamura G, Satodate R. Expression of cytokine genes 
and presence of enteroviral genomic RNA in endomyocardial biopsy tissues of myocarditis and dilated 
cardiomyopathy. Virchows Archiv. 1996;427(5):503-9. 
83. Negishi H, Osawa T, Ogami K, Ouyang X, Sakaguchi S, Koshiba R, et al. A critical link between 
Toll-like receptor 3 and type II interferon signaling pathways in antiviral innate immunity. Proceedings of 
the National Academy of Sciences. 2008;105(51):20446-51. 
84. Richer MJ, Lavallee DJ, Shanina I, Horwitz MS. Toll-like receptor 3 signaling on macrophages is 
required for survival following coxsackievirus B4 infection. PloS one. 2009;4(1):e4127. 
85. Gorbea C, Makar KA, Pauschinger M, Pratt G, Bersola JL, Varela J, et al. A role for Toll-like 
receptor 3 variants in host susceptibility to enteroviral myocarditis and dilated cardiomyopathy. Journal 
of Biological Chemistry. 2010;285(30):23208-23. 
86. Fairweather D, Yusung S, Frisancho S, Barrett M, Gatewood S, Steele R, et al. IL-12 receptor β1 
and Toll-like receptor 4 increase IL-1β-and IL-18-associated myocarditis and coxsackievirus replication. 
The Journal of Immunology. 2003;170(9):4731-7. 
87. Satoh M, Nakamura M, Akatsu T, Iwasaka J, Shimoda Y, Segawa I, et al. Expression of Toll-like 
receptor 4 is associated with enteroviral replication in human myocarditis. Clinical Science. 
2003;104(6):577-84. 
88. Pauschinger M, Doerner A, Kuehl U, Schwimmbeck PL, Poller W, Kandolf R, et al. Enteroviral RNA 
replication in the myocardium of patients with left ventricular dysfunction and clinically suspected 
myocarditis. Circulation. 1999;99(7):889-95. 
89. Fuse K, Chan G, Liu Y, Gudgeon P, Husain M, Chen M, et al. Myeloid differentiation factor-88 
plays a crucial role in the pathogenesis of coxsackievirus B3–induced myocarditis and influences type I 
interferon production. Circulation. 2005;112(15):2276-85. 
 29 
90. San Román JA, López J, Vilacosta I, Luaces M, Sarriá C, Revilla A, et al. Prognostic stratification of 
patients with left-sided endocarditis determined at admission. The American journal of medicine. 
2007;120(4):369. e1-. e7. 
91. Bustamante J, Tamayo E, Flórez S, Telleria JJ, Bustamante E, López J, et al. Toll-like receptor 2 
R753Q polymorphisms are associated with an increased risk of infective endocarditis. Revista Española 
de Cardiología (English Edition). 2011;64(11):1056-9. 
92. Golovkin AS, Ponasenko AV, Yuzhalin AE, Salakhov RR, Khutornaya MV, Kutikhin AG, et al. An 
association between single nucleotide polymorphisms within TLR and TREM-1 genes and infective 
endocarditis. Cytokine. 2015;71(1):16-21. 
93. Weinstock M, Grimm I, Dreier J, Knabbe C, Vollmer T. Genetic variants in genes of the 
inflammatory response in association with infective endocarditis. PloS one. 2014;9(10):e110151. 
94. Tsaganos T, Pelekanou A, Skiadas I, Giamarellos-Bourboulis EJ. Differences in cytokine 
stimulation between methicillin-susceptible and methicillin-resistant Staphylococcus aureus in an 
experimental endocarditis model. Journal of Infection and Chemotherapy. 2013;19(2):272-8. 
95. Banks J, Poole S, Nair SP, Lewthwaite J, Tabona P, McNab R, et al. Streptococcus sanguis secretes 
CD14-binding proteins that stimulate cytokine synthesis: a clue to the pathogenesis of infective 
(bacterial) endocarditis? Microbial pathogenesis. 2002;32(3):105-16. 
96. Gurses KM, Kocyigit D, Yalcin MU, Canpinar H, Yorgun H, Sahiner ML, et al. Monocyte toll-like 
receptor expression in patients with atrial fibrillation. American Journal of Cardiology. 
2016;117(9):1463-7. 
97. Zhang P, Shao L, Ma J. Toll-Like Receptors 2 and 4 Predict New-Onset Atrial Fibrillation in Acute 
Myocardial Infarction Patients. International heart journal. 2018;59(1):64-70. 
98. Gurses KM, Kocyigit D, Yalcin MU, Canpinar H, Evranos B, Canpolat U, et al. Platelet Toll-like 
receptor and its ligand HMGB-1 expression is increased in the left atrium of atrial fibrillation patients. 
Cytokine. 2018;103:50-6. 
99. Wang J, Xue L, Cao H, Cui F, Dai T, Chen Y. TLR2 was overexpressed independent of IL-6 in 
patients with valvular atrial fibrillation. Journal of biomedical research. 2011;25(3):178-84. 
100. Xu Q, Bo L, Hu J, Geng J, Chen Y, Li X, et al. High mobility group box 1 was associated with 
thrombosis in patients with atrial fibrillation. Medicine. 2018;97(13). 
101. Portegies M, Koudstaal PJ, Ikram M. Cerebrovascular disease.  Handbook of clinical neurology. 
138: Elsevier; 2016. p. 239-61. 
102. Fadakar K, Dadkhahfar S, Esmaeili A, Rezaei N. The role of Toll-like receptors (TLRs) in stroke. 
Reviews in the Neurosciences. 2014;25(5):699-712. 
103. Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, et al. 
Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in 
response to MyD88-and TRIF-dependent TLR signals, and TLR-independent signals. The Journal of 
Immunology. 2006;177(11):7551-8. 
104. Liesz A, Suri-Payer E, Veltkamp C, Doerr H, Sommer C, Rivest S, et al. Regulatory T cells are key 
cerebroprotective immunomodulators in acute experimental stroke. Nature medicine. 2009;15(2):192. 
105. Samarasinghe R, Tailor P, Tamura T, Kaisho T, Akira S, Ozato K. Induction of an anti-inflammatory 
cytokine, IL-10, in dendritic cells after toll-like receptor signaling. Journal of interferon & cytokine 
research. 2006;26(12):893-900. 
106. Downes CE, Wong CH, Henley KJ, Guio-Aguilar PL, Zhang M, Ates R, et al. MyD88 is a critical 
regulator of hematopoietic cell-mediated neuroprotection seen after stroke. PLoS One. 
2013;8(3):e57948. 
107. Jung DY, Lee H, Jung B-Y, Ock J, Lee M-S, Lee W-H, et al. TLR4, but not TLR2, signals 
autoregulatory apoptosis of cultured microglia: a critical role of IFN-β as a decision maker. The Journal of 
Immunology. 2005;174(10):6467-76. 
 30 
108. Aravalli RN, Hu S, Lokensgard JR. Inhibition of toll-like receptor signaling in primary murine 
microglia. Journal of neuroimmune pharmacology. 2008;3(1):5-11. 
109. Stevens SL, Ciesielski TM, Marsh BJ, Yang T, Homen DS, Boule J-L, et al. Toll-like receptor 9: a 
new target of ischemic preconditioning in the brain. Journal of Cerebral Blood Flow & Metabolism. 
2008;28(5):1040-7. 
110. Tang S-C, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. Pivotal role for neuronal Toll-
like receptors in ischemic brain injury and functional deficits. Proceedings of the National Academy of 
Sciences. 2007;104(34):13798-803. 
111. Cao C-x, Yang Q-w, Lv F-l, Cui J, Fu H-b, Wang J-z. Reduced cerebral ischemia-reperfusion injury 
in Toll-like receptor 4 deficient mice. Biochemical and biophysical research communications. 
2007;353(2):509-14. 
112. Hyakkoku K, Hamanaka J, Tsuruma K, Shimazawa M, Tanaka H, Uematsu S, et al. Toll-like 
receptor 4 (TLR4), but not TLR3 or TLR9, knock-out mice have neuroprotective effects against focal 
cerebral ischemia. Neuroscience. 2010;171(1):258-67. 
113. Brea D, Sobrino T, Rodríguez-Yáñez M, Ramos-Cabrer P, Agulla J, Rodríguez-González R, et al. 
Toll-like receptors 7 and 8 expression is associated with poor outcome and greater inflammatory 
response in acute ischemic stroke. Clinical immunology. 2011;139(2):193-8. 
114. Yang Q-w, Li J-c, Lu F-l, Ai-qing W, Xiang J, Zhang L-l, et al. Upregulated expression of toll-like 
receptor 4 in monocytes correlates with severity of acute cerebral infarction. Journal of Cerebral Blood 
Flow & Metabolism. 2008;28(9):1588-96. 
115. Ferronato S, Lira M, Olivato S, Scuro A, Veraldi G, Romanelli M, et al. Upregulated expression of 
toll-like receptor 4 in peripheral blood of ischaemic stroke patients correlates with cyclooxygenase 2 
expression. European Journal of Vascular and Endovascular Surgery. 2011;41(3):358-63. 
116. Xu X, Wen Z, Zhao N, Xu X, Wang F, Gao J, et al. microRNA-1906, a novel regulator of toll-like 
receptor 4, ameliorates ischemic injury after experimental stroke in mice. Journal of Neuroscience. 
2017;37(43):10498-515. 
117. Lin Y-C, Chang Y-M, Yu J-M, Yen J-H, Chang J-G, Hu C-J. Toll-like receptor 4 gene C119A but not 
Asp299Gly polymorphism is associated with ischemic stroke among ethnic Chinese in Taiwan. 
Atherosclerosis. 2005;180(2):305-9. 
118. Tomchuck SL, Zwezdaryk KJ, Coffelt SB, Waterman RS, Danka ES, Scandurro AB. Toll‐like 
receptors on human mesenchymal stem cells drive their migration and immunomodulating responses. 
Stem cells. 2008;26(1):99-107. 
119. Wang Zj, Zhang Fm, Wang Ls, Yao Yw, Zhao Q, Gao X. Lipopolysaccharides can protect 
mesenchymal stem cells (MSCs) from oxidative stress‐induced apoptosis and enhance proliferation of 
MSCs via Toll‐like receptor (TLR)‐4 and PI3K/Akt. Cell biology international. 2009;33(6):665-74. 
120. Waterman RS, Tomchuck SL, Henkle SL, Betancourt AM. A new mesenchymal stem cell (MSC) 
paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PloS 
one. 2010;5(4):e10088. 
121. Yao Y, Zhang F, Wang L, Zhang G, Wang Z, Chen J, et al. Lipopolysaccharide preconditioning 
enhances the efficacy of mesenchymal stem cells transplantation in a rat model of acute myocardial 
infarction. Journal of biomedical science. 2009;16(1):74. 
122. Hayashi C, Papadopoulos G, Gudino CV, Weinberg EO, Barth KR, Madrigal AG, et al. Protective 
role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral 
pathogen. The Journal of Immunology. 2012;189(7):3681-8. 
123. Ferrer M, Méndez-García C, Rojo D, Barbas C, Moya A. Antibiotic use and microbiome function. 
Biochemical pharmacology. 2017;134:114-26. 
 31 
124. Plaza-Diaz J, Gomez-Llorente C, Fontana L, Gil A. Modulation of immunity and inflammatory 
gene expression in the gut, in inflammatory diseases of the gut and in the liver by probiotics. World 
journal of gastroenterology: WJG. 2014;20(42):15632. 
125. Xu Y, Sharma D, Du F, Liu Y. The role of Toll-like receptor 2 and hypoxia-induced transcription 
factor-1α in the atrial structural remodeling of non-valvular atrial fibrillation. International journal of 
cardiology. 2013;168(3):2940-1. 
  
 32 
Table1. Summary of the most relevant studies investigating TLRs signaling pathways in animal 
model of CVD 
Author 
(Reference) 
Population 
(number) 
Investigated 
TLR or other 
component 
Chief findings 
Shimamoto et 
al. (52) 
Mouse TLR4 
Decrease infarct size after MI with blocking of 
TLR4 
Ao et al. (53) 
Mouse TLR4 
Decreased neutrophil infiltration and 
chemokines expression in TLR4-deficient hearts 
Chong et al. 
(54) 
Mouse TLR4 
Decreased inflammatory cytokines expression 
in myocardial tissue in TLR4-deficient mice 
Fallach et al. 
(55) 
Mouse TLR4 
Cardioprotective effect of myocardial TLR4 
deficiency during MI 
Feng et al. (56) 
Mouse MyD88 
Significantly smaller infarct size and better 
cardiac function after MI in MyD88-deficient 
Maekawa et al. 
(57) 
Mouse IRAK4 
Cardioprotective effect of deficiency of IRAK4 
against IRI 
Zacharowski et 
al. (58) 
Rat TLR4 
Decrease infarct size with administration of 
TLR4 agonist before myocardial reperfusion 
Ha et al. (62) 
Mouse PI3K 
Cardioprotective effect with administration of 
PI3K inhibitor 
Ha et al. (18) 
Mouse TLR2 
Cardioprotective effect with administration of 
TLR2 agonist 
Favre et al. 
(64) 
Mouse TLR2 
Smaller infarct size after cardiac ischemia in 
deficiency of TLR2  
Arslan et al. 
(63) Mouse TLR2 
Significantly improved cardiac function and 
smaller infarct size with administration of anti-
TLR2 antibody 
Oyama et al. 
(70) 
Mouse TLR4 
Decrease infarct size in deficiency of TLR4 
Shishido et al. 
(71) 
Mouse TLR4, TLR2 
Decreased ventricular remodeling after MI in 
deficiency of TLR4 and TLR2 
No association between infarct size and 
deficiency of TLR2 
Timmers et al. 
(72) Mouse TLR4 
Decrease ventricular remodeling and better 
systolic function after MI and higher collagen 
density in infarct area in TLR4-deficient 
Riad et al. (73) 
Mouse TLR4 
Decrease ventricular remodeling and better 
cardiac function after MI in TLR4 deficient 
Tavener et al. 
(75) Mouse TLR4 
Administration of LPS to TLR4-deficient in 
myocardium but TLR4-positive in circulating 
leukocytes leaded to myocardial dysfunction 
Binck et al. 
(76) 
Mouse TLR4 
No cardioprotective effect was observed with 
transplantation of TLR4-deficient bone marrow 
Zou et al. (77) 
Mouse TLR2 
Cardioprotective effect in deficiency of TLR2 
during sepsis 
Negishi et al. 
(83) 
Mouse TLR3 
More susceptibility to viral infection in TLR3-
deficient 
Richer et al. 
(84) 
Mouse TLR3 
Important role of TLR3 in controlling coxsackie 
virus infection 
Increase myocardial injury and risk of adverse 
clinical outcome in TLR3-deficient mice 
Gorbea et al. 
(85) 
Mouse TLR3 
Poor controlling of viral replication in TLR3-
deficient mice with enteroviral myocarditis 
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Fairweather et 
al. (86) 
Mouse TLR3 
Significantly lower viral replication and severity 
of myocarditis in TLR4 deficiency in myocytes 
Fuse et al. (89) 
Mouse MyD88 
Association between absence of MyD88 and 
higher survival in viral myocarditis 
Downes et al. 
(106) 
Mouse MyD88 
Larger infarct size after ischemic stroke in 
MyD88 deficient mice 
Jung et al. 
(107) 
Mouse TLR4 
Blocking of TLR4 leaded to releasing IFN-β and 
cells apoptosis 
Aravalli et al. 
(108) 
Mouse cell line TLR2 
Blocking of TLR2 prevented progression of 
microglial cells toward apoptosis 
Stevens et al. 
(109) 
Mouse TLR9 
Blocking of TLR9 made neuroprotective 
Tang et al. 
(110) 
Mouse TLR2, TLR4 
Elevation in expression of TLR2 and TLR4 
within 1 h after ischemic stroke 
Cao et al. 
(111) 
Mouse TLR2, TLR4 
Decrease in infarct size after stroke in TLR2 
and TLR4-deficient mice 
Hyakkoku et 
al. (112) 
Mouse 
TLR3,TLR4, 
TLR9 
Neuroprotective effect of TLR4 deficiency in 
brain ischemia but not with TLR3 and TLR9 
Xu et al. (116) 
Mouse TLR4 
High level of miR-1906 in ischemic and peri-
ischemic area 
Association between miR-1906 administration 
and decrease TLR4 level and size of infarct 
area and improvement in neurological function 
Tsaganos et 
al. (94) 
Rabbit TLR4 
Different pattern of TNF-α stimulation, 
independent to TLR4 mechanisms in methicillin-
susceptible and methicillin-resistant 
staphylococcus aureus endocarditis 
Banks et al. 
(95) 
Streptococcus 
sanguis TLR4 
Inhibition activation of monocytes by binding to 
a complex of TRL4 and CD14 by secreted 
components of Streptococcus sanguis 
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Table2. Summary of the most relevant studies investigating TLRs signaling pathways in CVD 
patients 
Author 
(Reference) 
Population 
(number) 
Investigated 
TLR or other 
component 
Chief findings 
Kiechl et al. 
(27) 
Human (n=810) TLR4 
Decreased risk of atherosclerosis in existence 
of Asp299Gly and Thr399Ile polymorphisms 
Labrum et al. 
(28) Human (n=3000) TLR4 
No association between Asp299Gly and 
Thr399Ile polymorphisms and intima-media 
thickness 
Netea et al. 
(29) 
Human (n=493) TLR4 
No association between Asp299Gly 
polymorphism and atherosclerosis 
Norata et al. 
(30) Human (n=1256) TLR4 
No association between Asp299Gly and 
Thr399Ile polymorphisms and intima-media 
thickness 
Ameziane et 
al. (31) 
Human (n=399) TLR4 
Decreased risk of MI in Asp299Gly 
polymorphism 
Boekholdt et 
al. (32) Human (n=885) TLR4 
Association between Asp299Gly polymorphism 
and decreased risk of cardiovascular event in 
patients receiving statin treatment 
Holloway et al. 
(33) Human (n=166) TLR4 
Association between Asp299Gly polymorphism 
and decreased risk of MI in patients receiving 
statin treatment 
Edfeldt et al. 
(34) 
Human (n=2774) TLR4 
Increased risk of MI in men in existence of 
Asp299Gly and Thr399Ile polymorphisms 
Zee et al. (36) 
Human (n=1390) TLR4 
No association between risk of MI and 
Asp299Gly polymorphism 
Koch et al. (35) 
Human (n=5264) TLR4 
No association between Asp299Gly and 
Thr399Ile polymorphisms and risk of MI 
Satoh et al. 
(37) Human (n=85) TLR4 
Increase level of TLR4 after MI and also higher 
TLR4 level in MI patients with HF compared 
with MI patients without HF 
Methe et al. 
(38) 
Human (n=118) TLR4 
Higher TLR4 level in patients with UA 
Birks et al. (49) 
Human (n=36) TLR4 
Higher TLR4 in patients with requiring 
ventricular assist devices 
Tidswell et al. 
(78) 
Human (n=300) TLR4 
No significant reduction in all-cause mortality in 
severe septic patients received Eritoran 
Satoh et al. 
(87) Human (n=49) TLR4 
Higher TLR4 level in patients with myocarditis 
Positive association between level of TLR4 and 
enteroviral RNA 
Brea et al. 
(113) Human (n=110) TLR3, TLR9 
No difference in expression of TLR3 and TLR9 
between patients with good and poor outcome 
after ischemic stroke 
Yang et al. 
(114) 
Human (n=65) TLR4 
Association between higher level of TLR4 and 
adverse neurological outcome 
Ferronato et al. 
(115) Human (n=60) TLR4 
Positive association between TLR4 and 
expression of COX-2 enzyme which can cause 
more CNS damage after ischemic stroke 
Lin et al. (117) 
Human (n=457) TLR4 
Increased risk of ischemic stroke in existence of 
Asp119Cys polymorphism 
Bustamante et 
al. (91) 
Human (n=131) TLR2, TLR4 
Increased risk of infective endocarditis with 
presence of TLR2 R735Q polymorphism 
Golovkin et al. Human (n=410) TLR2, TLR4, Decreased risk of infective endocarditis with 
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(92) TLR6 presence of TLR6 rs3775073 polymorphism 
Weinstock et 
al. (93) Human (n=333) TLR4 
No significant difference in genetic variants of 
TLR4 between patients with infective 
endocarditis and controls 
Zhang et al. 
(97) Human (n=251) TLR2, TLR4 
Significantly higher expression of TLR2 and 
TLR4 and their signaling proteins in patients 
with AF compared with MI patients without AF 
Gurses et al. 
(96) Human (n=172) TLR2, TLR4 
Significantly higher TLR2 and TLR4 in AF 
patients and expression level of monocyte TLR4 
was associated with AF recurrence 
Gurses et al. 
(98) 
Human (n=75) TLR2, TLR4 
Significantly higher level of peripheral blood and 
left atrial TLR2 and TLR4 in AF patients and 
also higher left atrial platelet TLR2 and TLR4 
level in persistent AF than patients with 
paroxysmal AF  
Wang et al. 
(99) Human (n=48) TLR2 
Higher level of TLR2 in AF patients and 
significantly higher of TLR2 level in paroxysmal 
AF compared to persistent AF patients 
Xu et al. (100) 
Human (n=45) TLR4, MyD88 
Significantly higher MyD88 and HMGB1 in AF 
patients with thrombus and no difference in 
level of TLR4 between AF patients with and 
without thrombus 
Xu et al. (125) 
Human (n=163) TLR2 
Significantly higher TLR2 level in patients with 
persistent AF compared to paroxysmal AF 
 
 36 
Figure1. Schematic view of TLRs signaling pathways. Downstream TLRs signaling is divided 
into two different pathways: MyD88-dependent and -independent signaling pathways, which 
after several steps ultimately resulted in proinflammatory gene expression and production of 
various cytokines and chemokines 
 
 
